What should I know about Regeneron?
Regeneron is a US biotechnology company based in Westchester County, New York. Leonard Schleifer and George Yancopoulos founded it in 1988, and it makes antibody and other biologic medicines for eye disease, cancer, allergic and inflammatory conditions, and infectious diseases. Schleifer is its chief executive. In the second quarter of 2026 it reported revenue of $4.3 billion, up 17% on a year earlier, and net income of $1.3 billion. Much of its income comes from Dupixent, which it develops with Sanofi.
What are Regeneron's main drugs?
Dupixent, for eczema, asthma and other conditions, is the biggest. Sales rose 38% to $6.0 billion in the second quarter of 2026, and Regeneron shares the profit. Regeneron books its own sales of Eylea HD, an eye drug (US sales of $596 million, up 52%), and Libtayo, a cancer immunotherapy ($489 million, up 30%). Praluent, a cholesterol drug, and Evkeeza, for a rare genetic cholesterol disorder, also grew. The new myeloma drug Lynozyfic made $17 million in its first sales.
What is Regeneron currently developing?
Regeneron says US and EU regulators have accepted applications for cemdisiran, a treatment for generalised myasthenia gravis, and that the European regulator has accepted an application for the gene therapy Otarmeni under accelerated review. Not every programme succeeded: a Phase 3 trial of fianlimab in melanoma missed its primary endpoints. Regeneron has also expanded its partnership with Sanofi, with $1 billion upfront and up to $7 billion in milestone payments, and repaid its Sanofi development balance, which it says will lift collaboration profits from the third quarter.
Have there been any controversies involving Regeneron?
In June 2020 the US Department of Justice sued Regeneron, alleging the company funnelled tens of millions of dollars into the Chronic Disease Fund charity to cover Medicare co-pays for its eye drug Eylea, in violation of anti-kickback law. Regeneron said the case had "no merit" and described its donations as lawful charitable contributions to an independent patient-assistance charity. Similar cases against Amgen, Pfizer and Johnson & Johnson had previously been settled for hundreds of millions of dollars.
Is Regeneron publicly traded, and how big is it?
Yes. Regeneron trades on the Nasdaq under the ticker REGN and is part of the S&P 500 and Nasdaq-100. Its market value was about $74.7 billion on 7 October 2026, with the shares at about $748. Its revenue was $14.34 billion in 2025, and in the second quarter of 2026 it reported revenue of $4.3 billion. It also pays a small dividend.